Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma☆,☆☆
Introduction
Studies on the natural history of chronic hepatitis B virus (HBV) infection have shown that active HBV replication contributes to the development of acute flare, hepatic decompensation, cirrhosis and hepatocellular carcinoma (HCC) [1]. Theoretically, cessation of HBV replication may reduce the complications and improve prognosis. Interferon alfa (IFN) has been used in the treatment of chronic hepatitis B for decades. Beneficial effects including hepatitis B e antigen (HBeAg)/HBV–DNA seroclearance, reduction of HCC development and better complication free survival have been documented [2], [3], [4], [5], [6], [7], [8], [9], [10], [11]. However, the effect on the prevention of cirrhosis and HCC development remains controversial [9], [10], [11]. The major reasons include relatively small sample size, low response rate, lack of adequate controls, short follow-up period and different age group at enrollment. To address these problems, the long-term outcomes were compared between 233 IFN-treated patients and 1:1 well-matched untreated controls. Considering the role of HBV genotype [12], it was also included in the analysis.
Section snippets
Study group
The study group (IFN-treated) consisted of 233 patients from 3 medical centers in Taiwan, including 176 patients from two randomized trials conducted in one center between 1986 and 1993, as described elsewhere [6], [9]. The remaining 57 were consecutive patients with active hepatitis who received IFN therapy as part of the clinical practice before end of 1995. All patients were HBeAg positive with active hepatitis demonstrated by a biopsy within 3 months before starting therapy, and no evidence
Results
During IFN treatment, 109 (46.8%) patients required dose reduction and two patients discontinued therapy because of severe malaise and psychosis, respectively. The long-term outcomes of IFN-treated and control group are compared in Table 2 based on intention to treat analysis.
Discussion
Although a variety of IFN regimens were used to treat patients in the present study, almost all were in the recommended range of 4–6 months [19], and the duration of IFN therapy was not a significant factor in multivariate analysis (Table 4). The results of these regimens as a group have confirmed our previous findings that IFN-therapy, particularly with corticosteroid priming, in HBeAg positive patients was associated with a higher cumulative rate of HBeAg/HBV–DNA seroclearance and reduced HCC
Acknowledgements
This work was supported by grants awarded to Y.-F. Liaw from the Department of Health (DOH90-HP-1004) and the Prosperous Foundation Taipei, Taiwan. The authors thank Ms. Ivy Cheng and SC Chu for excellent assistance.
References (36)
- et al.
Long-term follow up of patients with chronic hepatitis B treated with interferon alfa
Gastroenterology
(1997) - et al.
Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications
Hepatology
(2001) - et al.
Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study
Gastroenterology
(1986) - et al.
Determinants for sustained HBeAg response to lamivudine therapy
Hepatology
(2003) - et al.
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B
J Hepatol
(2001) - et al.
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy
Hepatology
(2003) - et al.
Hepatitis B genotypes and the response to interferon therapy
J Hepatol
(2000) - et al.
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C
Hepatology
(2002) - et al.
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
Gastroenterology
(2000) - et al.
Natural history differences in perinatally versus adult-acquired disease
Curr Hepat Rep
(2004)
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.
Ann Intern Med
Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis
Hepatology
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
N Engl J Med
Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. A pilot study
Cancer
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
Hepatology
Long-term remission of chronic hepatitis B after alpha-interferon therapy
Ann Intern Med
Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B
J Viral Hepat
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
Hepatology
Cited by (0)
- ☆
Financial support: The authors have no financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. YF Liaw has served as an advisory board member of Roche and Bristol Myers-Squibb.
- ☆☆
The authors who have taken part in this study declared that they have no relationship with the manufactures of the drugs involved either in the past or present and they received funding from Wellcome and Roche to carry our their research.